Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: Applicability for the development of novel oxazolidinones

Xenobiotica

Volumn 34, Issue 6, 2004, Pages 571-579

  Bhamidipati, R K ^a   Dravid, P V ^a   Mullangi, R ^a   Srinivas, N R ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

[No Author keywords available]

Indexed keywords

LINEZOLID; OXAZOLIDINONE DERIVATIVE;

ALLOMETRY; ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; MALE; MOUSE; NONHUMAN; RAT;

ACETAMIDES; ANIMALS; BODY SIZE; DOGS; DRUG DESIGN; HALF-LIFE; HUMANS; MALE; MICE; MODELS, ANIMAL; OXAZOLIDINONES; RATS; RATS, WISTAR;

ANIMALIA; CANIS FAMILIARIS; POSIBACTERIA;

EID: 3242746774     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250410001685719     Document Type: Article

References (26)

1. AMENT, P. W., JAMSHED, N. and HORNE, J. P., 2002, Linezolid: its role in the treatment of Gram-positive, drug-resistant bacterial infections. American Family Physician, 65, 663-670.
2. AVILES, P., PATEMAN, A., SAN ROMAN, R., GUILLEN, M. J., GOMEZ DE LASHERA, F. and GARGALLO-VIOLA, D., 2001, Animal pharmacokinetics and interspecies scaling of sordarin derivatives following intravenous administration. Antimicrobial Agents and Chemotherapy, 45, 2787-2792.
3. BOUZA, E. and MUNOZ, P., 2001, Linezolid: pharmacokinetic characteristics and clinical studies. Clinical Microbial Infections, 7, 75-82.
4. BOXENBAUM, H., 1984, Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metabolism Reviews, 15, 1071-1112.
5. BRIER, M. E., STALKER, D. J., ARONOFF, G. R., BATTS, D. H., RYAN, K. K., O'GRADY, M., HOPKINS, N. K. and JUNGBLUTH, G. L., 2003, Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrobial Agents and Chemotherapy, 47, 2775-2780.
6. FORD, C. W., ZURENKO, G. E. and BARBACHYN, M. R., 2001, The discovery of linezolid, the first oxazolidinone antibacterial agent. Current Drug Targets in Infectious Disorders, 1, 181-199.
7. HENDERSHOT, P. E., ANTAL, E. J., WELSHMAN, I. R., BATTS, D. H. and HOPKINS, N. K., 2001, Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanol-amine HCl, and dextromethorpan HBr. Journal of Clinical Pharmacology, 41, 563-572.
8. KHOR, S. P., MCCARTHY, K., DU PONT, M., MURRAY, K. and TIMONY, G., 2000, Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial. Journal of Pharmacology and Experimental Therapeutics, 293, 618-624.
9. MACGOWAN, A. P., 2003, Pharmacokinetic and pharmacodynamic profile of linezolid in healthy volunteers and patients with Gram-positive infections. Journal of Antimicrobial Chemotherapy, 51, 17-25.
10. MAHMOOD, I., 2001a, Interspecies scaling of maximum tolerated dose of anticancer drugs: relevance to starting dose for phase I clinical trials. American Journal of Therapeutics, 8, 109-116.
11. MAHMOOD, I., 2001b, Interspecies scaling: is a priori knowledge of cytochrome p450 isozymes involved in drug metabolism helpful in prediction of clearance in humans from animal data. Drug Metabolism and Drug Interaction, 18, 135-147.
12. MAHMOOD, I., 2002, Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metabolism and Drug Interaction, 19, 49-64.
13. MOELLERING, R. C., 2003, Linezolid: the first oxazolidinone antimicrobial. Annals of Internal Medicine, 138, 144.
14. PERRY, C. M. and JARVIS, B., 2001, Linezolid: a review of its use in the management of serious Gram-positive infections. Drugs, 61, 525-551.
15. PHARMACIA AND UPJOHN, 2000, Zyvox™ (linezolid) brochure for the anti-infective drug products advisory committee meeting (available at: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/ 3597b1ba.pdf).
16. SHIN, B. S., KIM, D. H., CHO, C. Y., PARK, S. K., CHUNG, S. G., CHO, E. H., LEE, S. H., JOO, J. H., KWON, H. S., LEE, K. C. and YOO, S. D., 2003, Pharmacokinetic scaling of SJ-8029, a novel anticancer agent possessing microtubule and topoisomerase inhibiting activities, species-invariant time methods. Biopharmaceutics and Drug Disposition, 24, 191-197.
17. SISSON, T. L., JUNGBLUTH, G. L. and HOPKINS, N. K., 2002, Age and sex effects on the pharmacokinetics of linezolid. European Journal of Clinical Pharmacology, 57, 793-797
18. SLATTER, J. G., ADAMS, L. A, BUSH, E. C, CHIBA, K, DALEY-YATES, P. T., FEENSTRA, K. L., KOIKE, S., OZAWA, N., PENG, G. W., SAMS, J. P., SCHUETTE, M. R. and YAMAZAKI, S., 2002, Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica, 32, 907-924.
19. 14C] linezolid to healthy human subjects. Drug Metabolism and Disposition, 29, 1136-1145.
20. STALKER, D. and JUNGBLUTH, G., 2003, Clinical pharmacokinetics of linezolid, a novel oxazolidinone antibacterial. Clinical Pharmacokinetics, 42, 1129-1140.
21. STALKER, D. J., JUNGBLUTH, G. L., HOPKINS, N. K. and BATTS, D. H., 2003, Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. Journal of Antimicrobial and Chemotherapy, 51, 1239-1246.
22. SUKBUNTHERNG, J., CROPP, G., HANNAH, A., WAGNER, G. S., SHAWVER, L. K. and ANTONIAN, L., 2001, Pharmacokinetics and interspecies scaling of a novel VEGF receptor inhibitor, SU5416. Journal of Pharmacy and Pharmacology, 53, 1629-1636.
23. WARD, K. W., PROKSCH, J. W., GORYCKI, P. D., YU, C. P., HO, M. Y., BUSH, B. D., LEVY, M. and SMITH, B. R., 2002, SB-242235, a selective inhibitor of p38 mitogen-activated protein kinase. II: in vitro and in vivo metabolism studies and pharmacokinetic extrapolation to man. Xenobiotica, 32, 235-250.
24. WELSHMAN, I. R., SISSON, T. A., JUNGBLUTH, G. L., STALKER, D. J. and HOPKINS, N. K., 2001, Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharmaceutics and Drug Disposition, 22, 91-97.
25. WIENKERS, L. C., WYNDALDA, M. A., FEENSTRA, K. L., GAO, P. and SLATER, J. G., 1999, In vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586. In Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA.
26. WYNALDA, M. A., MICHAEL, J. H. and LARRY, C. W., 2000, Oxidation of novel oxazolidinone antibiotic linezolid in human liver microsomes. Drug Metabolism Disposition, 20, 1014-1017.